



p56Lck Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

## p56Lck Positive Control

(Human, recombinant protein expressed in Sf9)  
Cat# CY-E1084

Lot No.  
For 100 Assays  
(1 unit /  $\mu\text{L}$  x 100  $\mu\text{L}$ )

### Product Description:

Catalytic domain of human Lck, corresponding to 217-509 a.a. containing a N-terminal GST tag and a C-terminal His tag, expressed in recombinant Baculovirus-infected sf9 cells. Purified by sequentially using GSH agarose and Ni-NTA agarose chromatography. The Lck Positive control is designed to use for CycLex Lck Kinase Assay/Inhibitor Screening Kit (Cat# CY-1084). The Lck Positive Control should be added to the well at 1 unit/well. For instance, diluted positive control 1:10, use 10  $\mu\text{L}$  for 1 assay. Unused Lck Positive Control should be stored at  $-70^{\circ}\text{C}$ .

**Product Size:** Recombinant Lck: 100 units/100  $\mu\text{L}$

**Formulation:** The Lck Positive Control is supplied frozen in a buffer containing 20mM Hepes-KOH (pH 7.5), 1 % BSA, 1mM EDTA, 2 mM DTT, 50mM NaCl, 0.03 % Brij35 and 50% glycerol.

**Source:** Human Lck containing N-terminal GST-tag and C-terminal His tag, expressed in sf9 cells.

**Molecular Weight:** Lck Positive Control demonstrates a single 62 kDa bands by SDS-PAGE analysis.

**Purity:** Lck Positive Control is greater than 75 % pure as determined by SDS-PAGE analysis.

**Substrates:** Lck phosphorylates poly[Glu, Tyr] 4:1 as a exogenous substrate.

**Inhibitors:** BMS-238497 and BMS-243117 are known as selective small molecule Lck inhibitor.

**Unit Definition:** One unit is defined as the amount of kinase required to incorporate 1 nmol of phosphate into the Lck (autophosphorylation) under oligomerized and activated condition per 60 minute at  $30^{\circ}\text{C}$ .

**Assay Conditions:** Assay activity of Lck in a 50  $\mu\text{L}$  reaction containing 20 mM Hepes KOH (pH 7.5), 4 mM  $\text{MgCl}_2$ , 2 mM  $\text{MnCl}_2$ , 1 mM DTT, 50  $\mu\text{M}$  [ $\gamma$ - $^{32}\text{P}$ ] ATP (1  $\mu\text{Ci}$ ), and 4  $\mu\text{g}$  of CycLex-"Tyrosine kinase-binding module". Start the reaction by adding 10 $\mu\text{L}$  of the enzyme, diluted 10-fold in a buffer containing 20 mM Hepes KOH (pH 7.5), 1 mM DTT, 0.03 % Brij35. Incubate for 30 minutes at  $30^{\circ}\text{C}$ . Terminate the reaction by adding 600  $\mu\text{L}$  of cold 10 % TCA solution containing 0.2 % Sodium pyrophosphate and stand on ice for 15 min. Filtrate acid insoluble material through GFC filters (Whatman Inc.), wash 4 times with 1 % TCA and rinse filters with ethanol. Dry filters and count in a liquid scintillation counter.

**Storage and Stability:** Stable for 12 months at  $-70^{\circ}\text{C}$  from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot enzyme to avoid repeated freezing and thawing.



p56Lck Positive Control

Product Data Sheet

**For Research Use Only, Not for use in diagnostic procedures**

**Related Products:**

\* CycLex Lck Kinase Assay/Inhibitor Screening Kit: Cat# CY-1084

\* CycLex Tyrosine Kinase Assay Kit Module-1: Cat# CY-2080

**References:**

1. Weiss, A., Littman, D. R. *Cell* **76**: 263-274, 1994
2. Abraham, N., Miceli, M. C., Parnes, J. R., Veillette, A. *Nature* **350**: 62-66, 1991
3. Straus, D. B., Weiss, A. *Cell* **70**: 585-593, 1992
4. Molina, T. J., Kishihara, K., Siderovski, D. P., van Ewijk, W., Narendran, A., Timms, E., Wakeham, A., Paige, C. J., Hartmann, K.-U., Veillette, A., Davidson, D., Mak, T. W. *Nature* **357**: 161-164, 1992
5. Levin, S. D., Anderson, S. J., Forbush, K. A., Perlmutter, R. M. *EMBO J.* **12**: 1671-1680, 1993
6. Abraham, N., Veillette, A. *Mol. Cell. Biol.* **10**: 5197-5206, 1990
7. Paige, L. A., Nadler, M. J., Harrison, M. L., Cassady, J. M., Geahlen, R. L. *J. Biol. Chem.* **268**: 8669-8674, 1993
8. Koegl, M., Zlatkine, P., Ley, S. C., Courtneidge, S. A., Magee, A. I. *Biochem. J.* **303**: 749-753, 1994
9. Shenoy-Scaria, A. M., Gauhen, L. K. T., Kwong, J., Shaw, A. S., Lublin, D. M. *Mol. Cell. Biol.* **13**: 6385-6392, 1993
10. Rudd, C. E., Trevillyan, J. M., Dasgupta, J. D., Wong, L. L., Schlossman, S. F. *Proc. Natl. Acad. Sci. USA.* **85**: 5190-5194, 1998
11. Veillette, A., Bookman, M. A., Horak, E. M., Bolen, J. B. *Cell* **55**: 301-308, 1988
12. Veillette, A., Sleckman, B. P., Ratnofsky, S., Bolen, J. B., Burakoff, S. J. *Eur. J. Immunol.* **20**: 1397-1400, 1990
13. Turner, J. M., Brodsky, M. H., Irving, B. A., Levin, S. D., Perlmutter, R. M., Littman, D. R. *Cell* **60**: 755-765, 1990
14. Glaichenhaus, N., Shastri, N., Littman, D. R., Turner, J. M. *Cell* **64**, 511-520, 1991
15. Collins, T. L., Uniyal, S., Shin, J., Strominger, J. L., Mittler, R. S., Burakoff, S. J. *J. Immunol.* **148**: 2159-2162, 1992

**PRODUCED BY**

CycLex Co., Ltd.  
1063-103 Terasawaoka  
Ina, Nagano 396-0002  
Japan  
Fax: +81-265-76-7618  
e-mail: [info@cyclex.co.jp](mailto:info@cyclex.co.jp)  
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.